UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000002889
Receipt number R000003515
Scientific Title Efficacy of administering at early stage of BCAA supplementation
Date of disclosure of the study information 2009/12/14
Last modified on 2020/03/31 17:39:54

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Efficacy of administering at early stage of BCAA supplementation

Acronym

Efficacy of administering at early stage of BCAA supplementation

Scientific Title

Efficacy of administering at early stage of BCAA supplementation

Scientific Title:Acronym

Efficacy of administering at early stage of BCAA supplementation

Region

Japan


Condition

Condition

compensated cirrhosis

Classification by specialty

Hepato-biliary-pancreatic medicine

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The effectiveness of administering at the early stage of the BCAA food in the compensatory cirrhosis patient to the glucose intolerance is examined.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Phase III


Assessment

Primary outcomes

75g oral glucose tolerance test, HOMA-IR (homeostasis model assessment-insulin resistance) and after 12 weeks from the beginning of the dairy branched-chain amino acid supplementation intake

Key secondary outcomes

Serum albumin revel, BTR, Zn, platelet, Quality of Life(SF-36) and Urinary 8-OHdG excretion after 12 weeks from the beginning of the dairy BCAA supplementation intake


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -but assessor(s) are blinded

Control

Active

Stratification

YES

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

Numbered container method


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

BCAA supplementation (BCAA3.2g) is taken 12 weeks continuously three times a day.

Interventions/Control_2

Dietary intake of 12 weeks according to usual nourishment guidance

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Compensated cirrhosis
2. Serum albumin revel; 3.5-4.0mg/dL
3. Patients who give documentary informed consent voluntarily
4. Patient who fills all of the above-mentioned 1-3

Key exclusion criteria

1. Decompensated cirrhosis
2. Patient with serious glucose intolerance
3. Patient who has allergy in element of AMINOFEEL
4. Patient who has infectious disease that becomes problem in clinical
5. Patient inappropriate for participating to this study decided by the attending physicians

Target sample size

40


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Shuhei Nishiguchi

Organization

Hyogo College of Medicine

Division name

Division of Hepatobiliary and Pancreatic Diseases

Zip code


Address

1-1 Mukogawa, Nishinomiya, Hyogo, JAPAN

TEL

0798-45-6472

Email



Public contact

Name of contact person

1st name
Middle name
Last name Masaki Saito

Organization

Hyogo College of Medicine

Division name

Division of Hepatobiliary and Pancreatic Diseases

Zip code


Address

1-1 Mukogawa, Nishinomiya, Hyogo, JAPAN

TEL

0798-45-6472

Homepage URL


Email

he-jishu@hyo-med.ac.jp


Sponsor or person

Institute

Hyogo College of Medicine

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2009 Year 12 Month 14 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2009 Year 09 Month 01 Day

Date of IRB

2009 Year 10 Month 15 Day

Anticipated trial start date

2009 Year 11 Month 01 Day

Last follow-up date

2011 Year 03 Month 01 Day

Date of closure to data entry

2011 Year 06 Month 01 Day

Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2009 Year 12 Month 14 Day

Last modified on

2020 Year 03 Month 31 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003515


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name